IMPRESS-Norway

– A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer
- EudraCT number: 2023-507894-16-00
- Clinicaltrials.gov: NCT04817956
About the study |
Study design |
Collaborative partners |
Update/publications |